폐경 후 estrogen의 결핍은 골회전을 증가시키며 골형성에 비해 골흡수의 상대적인 증가를 야기한다. 이러한 골흡수와 형성의 불균형은 골의 소실을 초래하게 되어 폐경 후 골다공증 의 원인으로 제시되고 있다. 골의 변화상태는 최근 침습적인 골생검 및 비침습적인 골밀도 의 측정에 의해 가능하나 보다 짧은 기간동안의 역동적 변화를 측정하는데는 어려움이 있다. 본 연구는 1995년 1월부터 1995년 10월까지 중앙대학교 의과대학 산부인과 갱년기 크리닉 을 처음 내원한 이전에 호르몬치료를 받지 않은 폐경 주변기 여성 28명, 자연폐경여성 55명, 수술적 폐경여성 5명을 대상으로 골흡수인자인 deoxypyridinoline과 골형성인자인 osteocalcin 을 측정하여 이들의 유용성과 골밀도와의 관계를 알아보고자 본 연구를 실시하여 다음과 같 은 결론을 얻었다. 1. 혈청에서 측정한 osteocalcin은 perimenopause군에서

The non-invasive assessment of bone turnover has received increasing attention over the past few years, because of the need of sensitive markers in clinical investigation of osteoporosis. The purpose of this study was to assess the availibility of the bone resorption marker and bone formation marker in menopause and to assess the correlation of bone markers and osteoporosis. This study was undergone from January 1995 to October 1995 retrospectively for total 88 postmenopause women who were not treated by hormone replacemetn therapy. The subjects comprised 28 healthy perimenioausal women; 55 healthy natural postmenopausal women; 5 women with surgical menopause. We measured serum osteocalcin as a bone formation marker and urinary deoxypyridinoline as a bone resorption marker. Bone mineral densities were also measured by Dual Energy X-ray Absortiometry(DEXA). The mean serum osteocalcin level in perimenopausal women was 6.40+-3.12ng/ml, and mean levels in potmenopausal women with duration of menopause for 12 to 48 months, 49 to 84 months, 85 to 120 months, over 121 months were 9.26+-5.89ng/ml, 9.01+-2.75ng/ml, 8.36+-4.99ng/ml, 9.88+-3.82ng/ml, respectively. The level in surgical menopausal women was 8.76+-5.24ng/ml. The mean serum osteocalcin levels were significantly higher in post- menopausal women with duration of menopause for 12 to 48 months(p<0.05), for 49 to 84 months(p<0.05), and over 121 months(p<0.01). The urinary deoxypyridinoline level in perimenopausal women was 5.67+-1.26 nMDpD/ mMCr, and the levels in postmenopausal women with duration of menopause for 12 to 48 months, 40 to 84 months, 85 to 120 months, over 121 months were 7.13+-1.35 nMDpD/mMCr, 5.14+-0.83 nMDpD/mMCr, 5.04+-1.11 nMDpD/mMCr, 6.09+-1.86 nMDpD/mMCr, respectively. The level in surgical menopausal women was 6.26+-1.35 nMDpD/mMCr. The urinary deox- pyridinoline level was significantly higher in postmenopausal women with duration of menopause for 12 to 48 months(p<0.01). There was a tendency that osteocalcin levels were increasing according to decrease in bone mineral density but osteocalcin levels were not statistically significant among 3 groups such as normal, osteopenic, and osteoporotic groups and there was also no significance in deoxypyridinoline levels among 3 groups. As a conclusion, there were no significant correlation between bone formation and resorption markers, indicated that there was imbalance in bone formation and resorption in menopause period. Also bone loss of menopause was peak in 2 to 4 years after menopause.